Somatic Cell Reprogramming via Defined Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming somatic cells to pluripotency are inefficient and raise ethical concerns, particularly with the use of oocytes in somatic cell nuclear transfer. Additionally, it is unclear whether terminally differentiated cells can be reprogrammed to pluripotency using defined factors.
Innovation Solution
Engineered somatic cells with endogenous pluripotency genes linked to selectable markers are used. These cells are treated with agents that alter chromatin structure or transfected with pluripotency genes, allowing for the selection and assessment of cells for pluripotency characteristics. The method also involves identifying agents and genes that contribute to reprogramming somatic cells to a less differentiated state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If somatic cell nuclear transfer is used to reprogram somatic cells, then reprogramming to pluripotency is achieved, but ethical concerns arise and efficiency is low
Solution Approach 1:
The patent extracts the reprogramming function from the oocyte cytoplasm (the harmful/controversial element) and replaces it with defined transcription factors (Oct4, Sox2, Klf4, c-Myc) that can be introduced via viral vectors. This eliminates the need for oocyte manipulation while maintaining the reprogramming capability, thus resolving the ethical concerns while improving efficiency through a more controllable method.
Solution Approach 2:
The patent uses viral vectors as intermediaries to deliver the reprogramming factors into somatic cells. Instead of directly using oocyte cytoplasm to reprogram nuclei, the viral vectors serve as a mediator to introduce the necessary transcription factors, achieving the same reprogramming effect through an ethically acceptable intermediate mechanism.
2Reliability
If fusion with embryonic stem cells is used for reprogramming, then epigenetic resetting occurs, but generation of 4N pluripotent cells limits therapeutic use
Solution Approach 1:
The patent extracts only the essential reprogramming function from embryonic stem cells (the transcription factors they express) and introduces them directly into somatic cells. This avoids the problematic cell fusion process that creates 4N cells, while still achieving epigenetic resetting and pluripotency through the targeted delivery of specific transcription factors via viral vectors.
3Productivity
If direct reprogramming with transcription factors is used, then iPS cells are generated, but initial cells were not normal requiring improvement
Solution Approach 1:
The patent optimizes multiple parameters including the combination of transcription factors (Oct4, Sox2, Klf4, c-Myc), their expression levels, the use of different viral vector systems, and culture conditions to improve the quality and normality of generated iPS cells while maintaining high generation efficiency. These parameter adjustments ensure the produced cells are epigenetically and developmentally indistinguishable from embryo-derived ES cells.
Data Source
AI summary
The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.